Replies to post #52228 on Biotech Values

[grandpatb]

I'm surprised you didn't credit au2man in the IV DNDN MB. Not nice!

[DewDiligence]

Excellent article. We all know of companies that complete myriad phase-2 trials with “encouraging” results for drug candidates that go nowhere. I consider the word encouraging in a PR reporting clinical data to be clearly negative in much the same way as the word interesting is used to describe a restaurant meal. Regards, Dew